Teva与Royalty Pharma合作加快白癜风治疗的开发速度。 Teva and Royalty Pharma partner to speed up a vitiligo treatment's development.

Teva制药工业和皇家药房公司建立了伙伴关系,以加快开发一种可能的维蒂里戈治疗方法,维蒂里戈是一种慢性皮肤病,造成色素流失。 Teva Pharmaceutical Industries and Royalty Pharma have entered a partnership to fast-track the development of a potential treatment for vitiligo, a chronic skin condition causing pigment loss. 该协议旨在通过临床试验和监管审查来推进药物的发展,目标是更快地为患者提供新的治疗。 The agreement aims to advance the drug through clinical trials and regulatory review, with the goal of bringing a new therapy to patients more quickly. 交易的财务条款没有披露。 The financial terms of the deal were not disclosed.